Polaryx Therapeutics, Inc. PLYX Deferred Tax Assets Patent License
Deferred Tax Assets Patent License at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept plyx:DeferredTaxAssetsPatentLicense.
The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Polaryx Therapeutics, Inc. 's deferred tax assets patent license.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's deferred tax assets patent license?
- Polaryx Therapeutics, Inc. (PLYX) reported deferred tax assets patent license of $852K in Q4 2025.
- What does deferred tax assets patent license mean?
- Tax benefits specifically tied to the company's patent and licensing activities.
- How do you interpret deferred tax assets patent license?
- Higher values indicate significant tax-deductible bases in intellectual property that can reduce future tax burdens.
- How does deferred tax assets patent license compare across companies?
- Specific to R&D-heavy industries like biotech and pharmaceuticals.